Pacific Edge (ASX:PEB) Beneish M-Score: -4.58 (As of Jun. 25, 2026)


ASX:PEB Pacific Edge Ltd ASX:PEB
42 GF Score
Price A$0.25
GF Value A$0.05
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Pacific Edge Beneish M-Score?

Pacific Edge ASX:PEB -3.85% 42 Beneish M-Score is -4.58 as of Jun. 25, 2026. GuruFocus rates ASX:PEB with a GF Score™ of 42/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Pacific Edge ranks better than 93.85% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.58 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Pacific Edge's Beneish M-Score or its related term are showing as below:

ASX:PEB' s Beneish M-Score Range Over the Past 10 Years
Min: -4.58   Med: -3.17   Max: -0.55
Current: -4.58

During the past 13 years, the highest Beneish M-Score of Pacific Edge was -0.55. The lowest was -4.58. And the median was -3.17.


Pacific Edge Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Pacific Edge's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Edge Beneish M-Score Chart

Pacific Edge Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.11 -1.66 -3.16 -3.20 -4.58

Pacific Edge Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.16 0.00 -3.20 0.00 -4.58

ASX:PEB vs TMO, DHR, IDXX: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, Pacific Edge's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Edge Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Pacific Edge's Beneish M-Score falls into.


ASX:PEB
42GF Score
Pacific Edge Ltd ASX:PEB
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacific Edge Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Pacific Edge for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9404+0.528 * 1+0.404 * 1.1344+0.892 * 0.4826+0.115 * 0.8022
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.6635+4.679 * -0.30679-0.327 * 1.3346
=-4.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was A$2.05 Mil.
Revenue was A$9.58 Mil.
Gross Profit was A$9.58 Mil.
Total Current Assets was A$11.48 Mil.
Total Assets was A$14.67 Mil.
Property, Plant and Equipment(Net PPE) was A$2.84 Mil.
Depreciation, Depletion and Amortization(DDA) was A$1.71 Mil.
Selling, General, & Admin. Expense(SGA) was A$17.02 Mil.
Total Current Liabilities was A$5.68 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.11 Mil.
Net Income was A$-29.82 Mil.
Gross Profit was A$1.30 Mil.
Cash Flow from Operations was A$-26.62 Mil.
Total Receivables was A$4.52 Mil.
Revenue was A$19.86 Mil.
Gross Profit was A$19.86 Mil.
Total Current Assets was A$28.02 Mil.
Total Assets was A$33.66 Mil.
Property, Plant and Equipment(Net PPE) was A$4.93 Mil.
Depreciation, Depletion and Amortization(DDA) was A$2.13 Mil.
Selling, General, & Admin. Expense(SGA) was A$21.20 Mil.
Total Current Liabilities was A$8.87 Mil.
Long-Term Debt & Capital Lease Obligation was A$1.08 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.05 / 9.583) / (4.517 / 19.857)
=0.21392 / 0.227476
=0.9404

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(19.857 / 19.857) / (9.583 / 9.583)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11.478 + 2.839) / 14.668) / (1 - (28.017 + 4.931) / 33.658)
=0.02393 / 0.021095
=1.1344

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=9.583 / 19.857
=0.4826

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.131 / (2.131 + 4.931)) / (1.712 / (1.712 + 2.839))
=0.301756 / 0.376181
=0.8022

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(17.023 / 9.583) / (21.204 / 19.857)
=1.776375 / 1.067835
=1.6635

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.105 + 5.681) / 14.668) / ((1.08 + 8.868) / 33.658)
=0.394464 / 0.295561
=1.3346

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-29.815 - 1.3 - -26.615) / 14.668
=-0.30679

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Pacific Edge has a M-score of -4.62 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -4.58 mean?
Pacific Edge (ASX:PEB) has a Beneish M-Score of -4.58 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pacific Edge and its competitors. According to the industry distribution chart, Pacific Edge ranks #12 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 6.2%.
Is Pacific Edge's Beneish M-Score too high?
Pacific Edge's current Beneish M-Score is -4.58. Based on the distribution chart, Pacific Edge ranks #12 out of 195 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Pacific Edge has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's Beneish M-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pacific Edge ranks #12 out of 195 companies for Beneish M-Score. This places Pacific Edge in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pacific Edge and its competitors. Pacific Edge's current Beneish M-Score is -4.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.25 — trading 400% above its estimated fair value. The current Beneish M-Score is -4.58. Pacific Edge's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current Beneish M-Score is -4.58 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Edge (ASX:PEB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued. The current stock price of A$0.25 is trading 400% above its estimated GF Value™ of A$0.05. GuruFocus considers Pacific Edge to be Significantly Overvalued.

Key valuation signals for ASX:PEB:

  • Beneish M-Score: -4.58
  • GF Value™: A$0.05 vs. price of A$0.25 (400% above fair value)
  • GF Score™: 42/100 with 8 warning signs

No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacific Edge Business Description

Address 87 Saint David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
42GF Score

Get the complete analysis for ASX:PEB

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.25
Price
A$0.05
GF Value